Bull and Bear

Figures converted from Indian rupees at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Bull and Bear

Verdict: No Edge — the entire debate collapses to one auditor's signature in the next 30-60 days. Bull and Bear are both internally consistent and rest on the same disclosed facts; what separates them is one binary event that is calendared, not speculative — the FY26 audit report due May-June 2026 from the auditor appointed in October 2025. Until that signature lands, the borrowing reduction, the 32% Q3 gross margin, and the 864-day inventory all support both readings. The cluster of resignations between July and October 2025 (two directors, statutory auditor Walker Chandiok, Company Secretary) tilts the burden of proof onto the bull, but the founder's $7.48 warrant subscription and the 50.44% un-pledged stake are not the moves of someone who knows the audit is unsignable. The honest call is to wait — committing capital either way today is a coin flip on a single document that prints in weeks.

Bull Case

Bull's price target is $0.369 (12-18 months), built on 1.5× FY27E book value (~$0.242) anchored to Insecticides India's 1.7× peer multiple, with a 12% governance discount and a ~10% inventory haircut already embedded; cross-checks to 14× FY27E EPS of ~$0.026. The primary catalyst is the FY26 audited annual report due May-June 2026 — a clean opinion plus inventory days under 500 converts the forensic discount into a re-rate. Disconfirming signal: audited FY26 inventory days above 600, or any qualification / emphasis-of-matter / key-audit-matter note on inventory, related-party transactions, or going concern — either ends the long.

Bear Case

Bear's downside target is $0.105/share (≈44% below $0.189 spot, 6-12 months), built on a book-value floor with a 40% inventory haircut: ~$45M write-down collapses Sep-2025 reported equity ($85M) to ~$40M against 36 cr post-bonus shares = ~$0.105 — the level the market briefly priced in the March-2026 $0.139 print before a relief bounce. Primary trigger is the FY26 audit (May-June 2026): a key-audit-matter or emphasis-of-matter on inventory valuation, related-party transactions, or going concern from the new auditor would force buy-side models to take the haircut explicitly; failing that, audited inventory days above 500 or formal warrant forfeiture by June 2026 each crystallizes the write-down. Cover signal: audited FY26 with (i) clean auditor opinion, (ii) inventory days below 300, AND (iii) consolidated CFO/NI above 0.7 — all three together.

The Real Debate

Verdict

No Edge — wait for the FY26 audit print. Bear carries marginally more weight on the body of evidence (the cumulative -0.43 CFO/NI ratio and the cluster of senior departures are harder to explain away than the bull's read of the same facts), but the asymmetry is not large enough to override the timing: the single most important tension — whether the 864-day inventory survives audit at carrying value — resolves in 30-60 days when Indian listed companies must file their audited FY26 results within 60 days of fiscal year-end. The bull could still be right, and the patent franchise plus the un-pledged 50.44% promoter stake plus the $7.48 warrant subscription are genuinely hard to reconcile with a coordinated exit thesis; if the new auditor signs clean and inventory days print under 500, the 0.79× P/B is too cheap and the re-rate to peer multiples is mechanical. The condition that flips this verdict to Lean Long is exactly what the bull names: clean FY26 opinion + audited inventory days under 500 + the $13.3M warrant balance paid in by 30 June 2026. The condition that flips it to Avoid / Lean Short is any qualification, emphasis-of-matter, or key-audit-matter from the new auditor, or audited inventory days above 600. Until one of those prints, this is a calendared binary, not an investable edge.